Related Experiment Video

Updated: May 25, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting the PI3K signaling pathway in cancer therapy

Chandra Bartholomeusz1, Ana Maria Gonzalez-Angulo

  • 1The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology and System Biology, Houston, TX 77030, USA.

Expert Opinion on Therapeutic Targets
|January 14, 2012
PubMed
Abstract

Insights

Targeted therapies inhibiting the PI3K/Akt/mTOR pathway show promise in cancer treatment. Further research is needed to identify biomarkers for patient selection and improve treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide 3-kinase (PI3K) signaling pathway regulates critical cancer cell processes like growth, motility, survival, and metabolism.
  • Aberrant PI3K pathway activity is prevalent in numerous cancers, including breast, bladder, prostate, thyroid, ovarian, and non-small cell lung cancer (NSCLC).
  • Targetable genetic alterations within this pathway present significant opportunities for developing precision cancer therapies.

Purpose of the Study:

  • To review genetic alterations in the PI3K/mammalian target of rapamycin (mTOR)/Akt pathway.
  • To discuss drugs targeting this pathway, including monotherapy, combination therapies, and chemotherapy regimens.
  • To highlight PI3K pathway inhibitors currently under clinical investigation for various human cancers.

Main Methods:

  • Review of genetic alterations in the PI3K/Akt/mTOR pathway.
  • Analysis of therapeutic strategies involving PI3K pathway inhibitors.
  • Examination of ongoing clinical trials for PI3K pathway-targeted agents.

Main Results:

  • Small-molecule inhibitors targeting the PI3K/Akt/mTOR pathway have demonstrated preliminary success in clinical trials.
  • Current clinical investigations are evaluating these inhibitors as single agents, in combination with other targeted therapies, or alongside chemotherapy.

Conclusions:

  • Small-molecule inhibitors targeting the PI3K/Akt/mTOR pathway show encouraging results in ongoing clinical trials.
  • Identifying molecular correlates for patient selection is crucial for enhancing treatment response.
  • Developing more effective screening methods to identify patients most likely to benefit from PI3K pathway inhibitors is essential.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...